Iarlori C - Search Results

1

Low-dose oral methotrexate treatment in chronic progressive multiple sclerosis.

Lugaresi A, Caporale C, Farina D, Marzoli F, Bonanni L, Muraro PA, De Luca G, Iarlori C, Gambi D. Lugaresi A, et al. Among authors: iarlori c. Neurol Sci. 2001 Apr;22(2):209-10. doi: 10.1007/s100720170026. Neurol Sci. 2001. PMID: 11603629 Clinical Trial.

2

Decreased integrin gene expression in patients with MS responding to interferon-beta treatment.

Muraro PA, Liberati L, Bonanni L, Pantalone A, Caporale CM, Iarlori C, De Luca G, Farina D, Lugaresi A, Gambi D. Muraro PA, et al. Among authors: iarlori c. J Neuroimmunol. 2004 May;150(1-2):123-31. doi: 10.1016/j.jneuroim.2004.01.002. J Neuroimmunol. 2004. PMID: 15081256

3

Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy.

De Luca G, Lugaresi A, Iarlori C, Marzoli F, Di Iorio A, Gambi D, Uncini A. De Luca G, et al. Among authors: iarlori c. J Neuroimmunol. 1999 Mar 1;95(1-2):190-4. doi: 10.1016/s0165-5728(98)00266-5. J Neuroimmunol. 1999. PMID: 10229130 Clinical Trial.

4

RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b.

Iarlori C, Reale M, Lugaresi A, De Luca G, Bonanni L, Di Iorio A, Feliciani C, Conti P, Gambi D. Iarlori C, et al. J Neuroimmunol. 2000 Jul 10;107(1):100-7. doi: 10.1016/s0165-5728(00)00261-7. J Neuroimmunol. 2000. PMID: 10808056

5

Reduction of free radicals in multiple sclerosis: effect of glatiramer acetate (Copaxone).

Iarlori C, Gambi D, Lugaresi A, Patruno A, Felaco M, Salvatore M, Speranza L, Reale M. Iarlori C, et al. Mult Scler. 2008 Jul;14(6):739-48. doi: 10.1177/1352458508088918. Epub 2008 May 27. Mult Scler. 2008. PMID: 18505779 Clinical Trial.

6

Interferon beta-1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis.

Iarlori C, Reale M, De Luca G, Di Iorio A, Feliciani C, Tulli A, Conti P, Gambi D, Lugaresi A. Iarlori C, et al. J Neuroimmunol. 2002 Feb;123(1-2):170-9. doi: 10.1016/s0165-5728(01)00487-8. J Neuroimmunol. 2002. PMID: 11880161

7

Interferon beta normalizes suppressor cell function in dysimmune neuropathies.

De Luca G, Lugaresi A, Iarlori C, Marzoli F, Uncini A, Gambi D. De Luca G, et al. Among authors: iarlori c. J Neuroimmunol. 1998 Feb;82(1):1-4. doi: 10.1016/S0165-5728(97)00170-7. J Neuroimmunol. 1998. PMID: 9526839

8

Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines.

Reale M, Iarlori C, Gambi F, Feliciani C, Salone A, Toma L, DeLuca G, Salvatore M, Conti P, Gambi D. Reale M, et al. Among authors: iarlori c. J Neuroimmunol. 2004 Mar;148(1-2):162-71. doi: 10.1016/j.jneuroim.2003.11.003. J Neuroimmunol. 2004. PMID: 14975597

9

IL-4 in vitro production is upregulated in Alzheimer's disease patients treated with acetylcholinesterase inhibitors.

Lugaresi A, Di Iorio A, Iarlori C, Reale M, De Luca G, Sparvieri E, Michetti A, Conti P, Gambi D, Abate G, Paganelli R. Lugaresi A, et al. Among authors: iarlori c. Exp Gerontol. 2004 Apr;39(4):653-7. doi: 10.1016/j.exger.2003.08.012. Exp Gerontol. 2004. PMID: 15050302

10

Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1 beta and interleukin-6 release from lymphocytes of Alzheimer's disease patients.

Reale M, Iarlori C, Gambi F, Lucci I, Salvatore M, Gambi D. Reale M, et al. Among authors: iarlori c. Exp Gerontol. 2005 Mar;40(3):165-71. doi: 10.1016/j.exger.2004.12.003. Epub 2005 Jan 8. Exp Gerontol. 2005. PMID: 15763393

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16 results

Search Page

Filters